|
From “undruggable” to impact: Allan Jordan on PARG inhibitors, research tools, and giving patients more tomorrows
|
10th August 2026
|
Read
|
|
The resistant MCF-7 and T47D cell lines I built myself – and why it was worth it
|
6th July 2026
|
Read
|
|
Rethinking drug discovery in glioblastoma
|
22nd June 2026
|
Read
|
|
Focus on: Colorectal cancer research tools
|
1st June 2026
|
Read
|
|
Model glioma heterogeneity, progression and treatment response with confidence
|
27th May 2026
|
Read
|
|
Focus on: Comprehensive models for ovarian cancer research and drug discovery
|
22nd May 2026
|
Read
|
|
Bridging the translational gap with TRACERx Lung Cancer PDX models
|
20th April 2026
|
Read
|
|
Brainbow antibodies: from Dawen Cai’s lab to researchers worldwide
|
16th March 2026
|
Read
|
|
Driving discovery with our cancer cell lines
|
10th December 2025
|
Read
|
|
Advancing pancreatic cancer research with the KPC cell line
|
24th November 2025
|
Read
|
|
Modelling treatment resistance in ovarian cancer: exploring the PEO series
|
25th June 2025
|
Read
|
|
pBABE’s Creation and Legacy: A Vector System That Propelled Cancer Research
|
19th May 2025
|
Read
|
|
Tumour Immunology – turning cancer’s weapons against itself
|
16th November 2023
|
Read
|
|
Targeting the difficult-to-drug protein – MYC
|
4th September 2023
|
Read
|
|
Brainbow Antibodies
|
16th February 2023
|
Read
|
|
Plasmax™ – Meet the inventor
|
11th November 2020
|
Read
|
